Cornea

Skip Navigation LinksHome > October 2011 - Volume 30 - Issue 10 > Combined Use of Subconjunctival and Intracorneal Bevacizumab...
Cornea:
doi: 10.1097/ICO.0b013e31821379aa
Clinical Science

Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization

Yeung, Sonia N MD, PhD, FRCSC; Lichtinger, Alejandro MD; Kim, Peter MBBS(Hons), FRANZCO; Amiran, Maoz D MD; Slomovic, Allan R MA, MD, FRCSC

Collapse Box

Abstract

Purpose: To report on the safety and clinical use of combined subconjunctival and intracorneal bevacizumab for corneal neovascularization.

Methods: The charts of 12 consecutive patients with corneal neovascularization who received combined subconjunctival and intracorneal injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Patients received 1 to 3 injections of 2.5 mg of bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal). Morphological changes were assessed clinically by 1 investigator.

Results: Combined subconjunctival and intracorneal injections of bevacizumab were effective and well-tolerated. No significant ocular or systemic adverse events were observed during 6.4 months (range, 0.25-22 months) of follow-up. All patients showed a reduction in the neovascularized area.

Conclusions: Short-term results suggest that combined subconjunctival and intracorneal injections of bevacizumab are an effective method for reducing corneal neovascularization. It may be a useful option or adjunct to other treatments in stabilizing or improving vision.

© 2011 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.